SIZE XSSIZE SMSIZE MDSIZE LG

HOPA is committed providing high quality education that is strongly integrated with HOPA’s core passion to support pharmacy practitioners and promote and advance Hematology/Oncology Pharmacy to optimize the care of individuals affected by cancer. HOPA strives to become the destination of choice for quality education focused on creating competent hematology/oncology pharmacists with sound domain knowledge, skills and managerial acumen.  Below is the full spectrum of education offerings – you may also sort by content area, date, delivery method, and if it offers BCOP recertification credit.

BCOP Oncology Pharmacy Updates Course

The BCOP Oncology Pharmacy Updates Course is an educational program designed for the practicing advanced level Board Certified Oncology Pharmacist. Covering new and ongoing therapeutic developments that have emerged within the last three years, Updates Course will provide you with up-to-date information, including recently published or ongoing studies from the past 2–3 years that you can immediately apply to your practice.

Highlights

  • Learn about promising research and new treatment regiments.
  • Get clinical updates on treatment of tumor types and new supportive care therapies.
  • Find an overview of common clinical and technical issues in the hematology/oncology clinical setting.

Module 1 – Breast Cancer Update: Considerations for Adjuvant Therapy and Treatment Pathways/Options for Advanced/Metastatic Disease

Module 2 - Updates in the Management of Prostate Cancer

Module 3 – Changes in the Treatment Landscape of Pediatric Acute Myeloid Leukemia

Module 4 – Is it really a no-brainer? Immunotherapy in Gliomas

Module 5 – Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia (CML): When to Stop and Go

Module 6 – Molecular Pathways, Fast and Slow Cancer Targets

Module 7 – Updates in the Management of Advanced and Metastatic Melanoma

Module 8 – Updates in the Management of Renal Cell Carcinoma

Module 9 – Updates on the Heart and Soul of Cardio-Oncology

Each module or session will include a recording of the faculty presenting their topic, a pre-test and BCOP post-test. You will also have the opportunity to pre-submit questions to the faculty via This email address is being protected from spambots. You need JavaScript enabled to view it. or attend their designated Office Hours where you will have the opportunity to ask your own questions and hear answers to the pre-submitted questions.

If you are unable to attend these Office Hours, you will be able to listen to these sessions as well in HOPA’s My Education Library. You may choose to complete all or select individual sessions, receiving BCOP credit for each completed module which achieves a passing score.

HOPA Member Price: $225
Non-Member Price: $325

Purchase now

The 2019 BCOP Updates Course is also a part of the 2019 BCOP Program Bundle. If you’ve already purchased the 2019 BCOP Program Bundle, you can access your Updates Course in My Education Library.

Accreditation Statement:

 logo acpeThe Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE test must be completed by December 31, 2019.

education speaker bpslogo The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved. Test must be completed by December 31, 2019.

Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.

Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.


Module 1 - Breast Cancer Update: Considerations for Adjuvant Therapy and Treatment Pathways/Options for Advanced/Metastatic Disease   (1.0 Contact Hours)

Description: The target audience for this session is oncology clinical pharmacists and residents who hope to gain a better understanding of the changes in the current treatment landscape of managing patients with breast cancer. During this session, recent data on the role of adjuvant therapy in early-stage patients and duration/timing/sequencing thereof will be discussed and real-world practice considerations in approach will be reviewed. An update and overview of treatment pathways and options for advanced/metastatic HR+, HER2+, and triple negative breast cancer will be provided, and the data surrounding the use of CDK4/6 inhibitors and PARP inhibitors in the advanced/metastatic setting and considerations when choosing these therapies will be examined in further detail. Clinical and practical considerations in therapeutics from a patient-specific approach will also be discussed within the context of the above topics.

Learning Objectives
  • Identify optimal early-stage breast cancer patients who should receive adjuvant therapy
  • Examine the timing, sequencing, and duration of adjuvant therapy and recognize optimal candidates for extended adjuvant therapy
  • Explain treatment pathways and options for HR+, HER2+, and TNBC in the advanced/metastatic setting
  • Optimally select a CDK4/6 inhibitor regimen in a patient with advanced/metastatic breast cancer and monitor for/manage side effects
  • Recognize MBC candidates for PARP inhibitor therapy

 MBarbee

Meagan Barbee, PharmD BCOP
Dr. Barbee is the Clinical Coordinator of Oncology Pharmacy at Emory Healthcare/Winship Cancer Institute in Atlanta, GA. Her practice site is the breast cancer clinic, and she also serves as the PGY-2 Oncology Residency Program Director and Adjunct Clinical Instructor at Mercer College of Pharmacy. Dr. Barbee received her Bachelor’s in Biochemistry from Georgia Institute of Technology and her PharmD from Mercer University. She completed both her PGY-1 and PGY-2 Oncology residencies at Emory.

Disclosure: Eli Lilly – A - NC

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-19-001-H04-P.

Activity Type: Application


Module 2: Updates in the Management of Prostate Cancer (1.0 Contact Hours)

Description: Oncology pharmacists play a pivotal role in collaborating with oncology providers in providing treatment options, which is key to advancing safe, effective care to our prostate cancer patients. This BCOP session will highlight the recent updates in the NCCN guidelines and outline the data supporting these changes. This presentation will speak to the data supporting new therapies for patients with castration-naïve and non-metastatic castration-resistant prostate cancer. In addition, this presentation will highlight recent changes in metastatic castration-resistant prostate cancer. This presentation will provide knowledge which will improve the practice of oncology pharmacists in the outpatient setting.

Learning Objectives

  • Examine the changes in risk stratification and staging workup of prostate cancer
  • Interpret the data supporting use of abiraterone in metastatic castration-naive prostate cancer patients
  • Assess the use of apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer patients
  • Summarize the adverse event profile of apalutamide, enzalutamide, and abiraterone
  • Evaluate appropriate options for metastatic castration resistant prostate cancer patients

SSmith

Sara Smith, PharmD BCOP
Sara Moran Smith is a Board Certified Oncology Clinical Pharmacist at M Health Maple Grove Cancer Center in Maple Grove, Minnesota and has been there for two years post residency. She obtained her PharmD from the University of Minnesota College Of Pharmacy. Thereafter, she completed a PGY-1 residency at the University of Minnesota Medical Center and a PGY-2 residency specializing in oncology at M Health Maple Grove Cancer Center. Sara has a passion for education. She has served on the HOPA Oral Chemotherapy Patient Education Task Force and leads a number of educational committees at the cancer center.

Disclosure: Takeda – C - H

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-19-002-H04-P.

Activity Type: Application


Module 3: Changes in the Treatment Landscape of Pediatric Acute Myeloid Leukemia (1.0 Contact Hours)

Description: Pediatric acute myeloid leukemia (AML) accounts for 20% of all childhood leukemia and more than 50% of the leukemia deaths. The limits of conventional chemotherapy and treatment intensification have been reached. Overall survival has improved from 50% to 60-70% over the past decade due to improvement in supportive care measures and a more definite consensus for the role of stem cell transplant; however, novel therapy is needed to increase the survival rate. Recent published literature has delineated the prognostic value of minimal residual disease (MRD) and identified prognostic cytogenetic and molecular subgroups that may be targeted with novel agents (CD33, FLT3, others). This session will highlight the major changes in the treatment landscape of pediatric AML.

Learning Objectives

  • Describe the current treatment utilized for pediatric acute myeloid leukemia (AML)
  • Identify molecular and cytogenetic subtypes of pediatric AML and respective emerging therapies for these targets
  • Evaluate the impact of minimal residual disease (MRD) on risk stratification in pediatric AML
  • Summarize select supportive care measures employed during treatment for pediatric AML

 Jennifer Thackray

Jennifer Thackray, PharmD BCOP BCPPS
Jennifer Thackray is a Pediatric Oncology Clinical Pharmacy Specialist at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, NY. Dr. Thackray earned her Doctor of Pharmacy degree from The University of Oklahoma College of Pharmacy in 2009. She completed an ASHP-accredited PGY-1 Pharmacy Practice Residency (2010) and a PGY-2 Pediatric Pharmacotherapy Specialty Residency (2011) at the University of North Carolina Health Clinics in Chapel Hill, NC. Dr. Thackray is board certified in pharmacotherapy and pediatric pharmacotherapy. Dr. Thackray joined the MSK Department of Pharmacy in 2011, initially practicing in the pediatric oncology inpatient setting. Over her tenure at MSK, Dr. Thackray has assisted in developing pediatric clinical services in the outpatient leukemia clinic and the outpatient sarcoma clinic. Her clinical practice includes rotating between inpatient oncology, outpatient leukemia and outpatient neuro-oncology clinical services. Currently, Dr. Thackray serves as a clinical preceptor in these areas, a PGY-2 resident mentor and a research mentor for PGY-2 resident research projects. Dr. Thackray's clinical interests and research efforts include pediatric oncology supportive care measures (i.e., chemotherapy-induced nausea and vomiting, venous thromboembolism, menses suppression, etc), pharmacogenetics and clinical guideline development within international organizations. Dr. Thackray is an active member of the American Society of Health-System Pharmacists (ASHP), American College of Clinical Pharmacy (ACCP), Children’s Oncology Group (COG), Clinical Pharmacogenetics Implementation Consortium (CPIC), Hematology/Oncology Pharmacy Association (HOPA) and Pediatric Pharmacy Advocacy Group (PPAG).

Disclosures: Spouse is an employee of Equashield.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-19-003-H04-P.

Activity Type: Application


Module 4: Is it really a no-brainer? Immunotherapy in gliomas (1 Contact Hour)

Description: Gliomas account for 1-2% of all cancer types, with glioblastoma (GBM) being the most common type of glioma as well as the most aggressive. The current standard of care treatment for glioblastoma (GBM) consists of surgery, radiotherapy, and chemotherapy (most commonly with temozolomide).1 Despite treatment, prognosis remains poor and mostly all patients will eventually progress or recur. Overall survival for these patients is less than 20 months and median survival for recurrent GBM is 7.5 months.2,3 Current treatment options for recurrent or progressive GBM are limited and have not been shown to improve overall survival. More recently, with the success of immunotherapy in the treatment of other cancer types, various treatment options for GBM have been utilizing different forms of immunotherapy. This session will discuss and educate pharmacists on these different immunotherapy approaches including vaccines, oncolytic viruses, CAR-T cells, and immune checkpoint inhibitors that are being investigated for GBM and other high grade gliomas.4-9

References:

  1. Wen PY et al. N Engl J Med 2008, 359:492-507
  2. Lamborn KR et al. Neuro Oncol 2008, 10:162-170
  3. Stupp R  et al. N Engl J Med 2005, 352:987-996
  4. Weller M, et al. Lancet Oncol 2017;18:1373–85. 
  5. Lang FF et al. J Clin Oncol. 2018: 36, (14):suppl1419-1427.
  6. Desjardans et al. N Engl J Med. 2018 Jun 26. doi: 10.1056/NEJMoa1716435
  7. Migliorini D et al. Clin Cancer Res. 2018;24(3):535-540
  8. Reardon DA et al. Neuro-Oncology. 2017;19:iii21
  9. Reardon DA et al. J Clin Oncol. 2017: 35(15):suppl 2042-2042.

Learning Objectives

  • Describe current standard of care upfront treatment strategies for GBM
  • Evaluate the use and role of checkpoint inhibitors for the treatment of GBM
  • Summarize data on investigational agents including vaccines and oncolytic viruses and their role in the treatment of GBM

PYerram

Prakirthi Yerram, PharmD BCOP BCPS
Prakirthi Yerram is an Oncology Clinical Pharmacy Specialist at Memorial Sloan Kettering Cancer Center. She is from Parsippany, NJ and completed her Doctor of Pharmacy from Ernest Mario School of Pharmacy at Rutgers University in New Brunswick, NJ in 2014. She completed a PGY-1 Pharmacy Practice Residency at Yale- New Haven Hospital in New Haven, CT in 2015 and a PGY-2 Hematology/Oncology Pharmacy Residency at Duke University Hospital in Durham, NC in 2016. After completing residency, Dr. Yerram began her career at Memorial Sloan Kettering working with the neuro-oncology service as a Clinical Pharmacy Specialist. Dr. Yerram is board certified in pharmacotherapy and oncology pharmacy.

Disclosures: Pfizer – C - H

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-19-004-H04-P.

Activity Type: Application


Module 5: Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia (CML): When to Stop and Go (1 Contact Hour)

Description: There has been recent evidence for stopping tyrosine kinase inhibitors (TKIs) in select patients with chronic myeloid leukemia (CML) as well as the use of these agents in the pediatric population. This session will review the literature on both of these topics and make recommendations on appropriate timing to start or stop these agents in these patient populations. The targeted audience will be hematology/oncology pharmacists who participate in the care of pediatric or adult CML patients.

Learning Objectives

  • Analyze recent literature on timing of TKI discontinuation in adult patients with CML
  • Apply patient- and disease-specific factors to daily practice when determining ideal candidates  for TKI discontinuation in adult CML
  • Identify barriers to TKI therapy in pediatric CML
  • Select the most appropriate TKI for pediatric CML based on patient- and disease specific factors

Seyyedeh Saneeymehri

Seyyedeh Saneeymehri, PharmD BCOP BCPS
Seyyedeh Saneeymehri is a Leukemia Clinical Specialist at Emory University Hospital/Winship Cancer Institute. After completing a PGY-2 in hematology/oncology at Moffitt Cancer Center in July of 2015, Seyyedeh worked in BMT for 2.5 years. She recently transitioned into her role at Emory and moved back home to Atlanta where her family and friends reside. Her interests include hiking, volleyball, kickboxing, and travelling.

Disclosures:Pfizer – A – H, Janssen—Pharmacyclics – A - H

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-19-005-H04-P.

Activity Type: Application


Module 6: Molecular Pathways, Fast and Slow Cancer Targets (1.5 Contact Hour)

Description: Due to the expanding data in understanding molecular targeted pathways and precision medicine in the field of oncology, oncology pharmacists need to be aware of the history of genomically guided therapy and the development of future targeted therapies. This activity will educate pharmacists on advances in molecular pathways, review the history of genomic pathways as well as novel advances in targeted therapeutics.

Learning Objectives

  • Review the diagnostic analysis of next generation sequencing in tumor tissue
  • Discuss clinical trials that have used genotyping to guide therapy in oncologic malignancies
  • Identify the next wave of target therapies and trials currently under development for the treatment of cancer

Patrick Kiel

Patrick Kiel, PharmD BCOP BCPS
Patrick J. Kiel, PharmD BCPS BCOP, is a Clinical Pharmacy Specialist at Indiana University (IU) Simon Cancer Center in Indianapolis, Indiana. He received his Doctor of Pharmacy degree from Midwestern University Chicago College of Pharmacy. Dr. Kiel completed his PGY-1 residency at Rush University Medical Center in Chicago, Illinois, and his PGY-2 specialty residency in hematology/oncology at Indiana University Hospital. He provides clinical services for the Precision Genomic Program at the IU Simon Cancer Center. He holds academic appointments to the Department of Medicine at the IU School of Medicine, Purdue University School of Pharmacy and Pharmaceutical Sciences, and Butler University College of Pharmacy.

Dr. Kiel serves on the IU Institutional Review Board (IRB) and IU Cancer Center Scientific Review Committee. He is published in peer-reviewed journals, and his research interests include genomically guided therapy in patients with refractory metastatic cancer, novel drug therapy for aggressive lymphomas and leukemia’s as well as supportive care.

Disclosures:Takeda – SP – H, Celgene – SP – H, Genentech – SP – H, Gilead – SP - H.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hours (.15 CEUs) under the ACPE universal activity number 0465-0000-19-006-H04-P.

Activity Type: Application


Module 7: Updates in the Management of Advanced and Metastatic Melanoma (1.5 Contact Hour)

Description: Melanoma is the 5th most common cancer in the United States with 91,270 new cases estimated in 2018.1 The rates for new cases have been increasing 1.5% each year although death rates have been decreasing.1 While the majority of patients present with localized disease, 9% will present with regional disease and 4% will present with distant metastatic disease.1 Fortunately, the number of therapies has grown with improved outcomes including utilizing newer therapies in the adjuvant setting. This session will focus on targeted therapy and immunotherapy in both the adjuvant and metastatic setting.

Learning Objectives

  • Discuss treatment options in the adjuvant setting for patients with advanced melanoma
  • Analyze talimogene larherparepvec in the setting of advanced melanoma
  • Discuss treatment option in the metastatic melanoma setting and compare that to the adjuvant setting
  • Briefly review management of immunotherapy adverse effects

Shawna Kraft

Shawna Kraft, PharmD BCOP
Shawna Kraft completed her PharmD at the University of Michigan, College of Pharmacy in 2006. She remained at the University of Michigan to complete her PGY-1 and PGY-2 oncology residency.

Shawna Kraft is currently a Clinical Pharmacist at the University of Michigan Cancer Center in oncology and Clinical Assistant Professor at the University of Michigan College of Pharmacy. Additionally, she is the program director for the PGY-2 Oncology residency at the University of Michigan. She is actively involved in the Michigan Pharmacists Association, the Michigan Society of Health System Pharmacists, and the Hematology/Oncology Pharmacy Association.

Disclosures: No financial relationships exist with commercial interests.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hours (.15 CEUs) under the ACPE universal activity number 0465-0000-19-007-H04-P.

Activity Type: Application


Module 8: Updates in the Management of Renal Cell Carcinoma (1 Contact Hour)

Description: This session will examine new treatment options for renal cell carcinoma. Until recently, the standard of care after local therapy has been active surveillance. New data suggests there may be a role for adjuvant systemic therapy, although this is still being debated and actively studied in clinical trials. In addition, there are new treatment options in metastatic disease based on highly robust outcomes in clinical trials, particularly in the 1st -line setting. These different options will be reviewed. Future treatment approaches will also be presented.

Learning Objectives

  • Explain the role of adjuvant therapy in renal cell carcinoma
  • Use risk stratification models to direct treatment in metastatic renal cell carcinoma
  • Compare FDA-approved treatment options in metastatic renal cell carcinoma in the 1st-line setting
  • Identify patient-specific and disease-related factors to determine therapy in metastatic renal cell carcinoma

 

Stacy Lisi

Stacy Lisi, PharmD BCOP CPP

  • Clinical Pharmacist, Genitourinary Oncology Clinic, Duke Cancer Center, Durham, NC, since 2015
  • Previously: Clinical Pharmacy Specialist, Rutgers Cancer Institute of NJ (12 years)
  • PharmD: University of North Carolina at Chapel Hill (1998)
  • PGY-1: The Ohio State University Medical Center
  • PGY-2: Nationwide Children’s Hospital

Disclosures: No financial relationships exist with commercial interests.

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-19-008-H04-P.

Activity Type: Application


Module 9: Updates on the Heart and Soul of Cardio-Oncology (1.0 Contact Hours)

Description: The approval of more than 60 novel targeted therapies has increased the response rates and survivability of many types of cancer. This increase in survival is often accompanied with an increase in the toxicities associated with some of the chemotherapy and targeted agents. Cardiac toxicities have been seen for decades with the anthracyclines, but now specific targeted agents such as VEGF inhibitors and tyrosine kinase inhibitors are unveiling their own specific cardiotoxicities. This session will review patients’ risk factors for the development of cardiotoxicity associated with chemotherapy and review appropriate guidelines for prevention and monitoring. The latest clinical trials evaluating prevention of cardiotoxicity will be reviewed. The newest guidelines and clinical trials regarding utilization of direct oral anticoagulants in cancer patients with thromboembolic disease will be discussed. This course will also provide an overview of cardiovascular related toxicities of newer oncology drugs including immunotherapy.

Learning Objectives

  • Identify patients who may be at high risk for cardiotoxicity and how to monitor these patients
  • Interpret newest clinical trials for prevention  of cardiotoxicity
  • Analyze most recent guidelines and trials for treating patients with venous thromboembolism identifying when direct oral anticoagulants may be warranted
  • Evaluate cardiotoxicities of new oncology drugs and immunotherapies

Jamie Shapiro

Jamie Shapiro, PharmD BCOP
Jamie Shapiro is a Clinical Oncology Pharmacist practicing in malignant hematology and stem cell transplantation at Moffitt Cancer Center. She completed her PGY-2 at MD Anderson Cancer Center in Houston, Texas where she stayed on to work in stem cell transplant for a few years before moving to Tampa, FL to work at Moffitt Cancer Center. She has been at Moffitt for the past 9 years. She has previously served as chair of the American Society of Bone Marrow Transplant (ASBMT) Pharmacy Special Interest Group. She has been a member of different committees within HOPA and is currently a member of the HOPA BCOP Updates Committee. Her areas of interest include supportive care, immunotherapy, GVHD, and novel agents for malignant hematology.

Disclosures: Tesaro – A – H, Heron – A - H

Target Audience

This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-19-009-H04-P.

Activity Type: Application

 

 

 

 

xs
sm
md
lg